statement
Rheumatoid arthritis may be a disease that requires suppression of pathogenic autoantibodies to a very deep level to confirm efficacy, consistent with J&J's nifocalimab failing in rheumatoid arthritis with a low ACPA antibody reduction rate.
A statement by 현대차증권 제약/바이오/의료기기 김현석. Statements are as reported by the cited publishers — not verified by DecisionGateway.
이는 류마티스관절염이 질병의 원인이 되는 자가항체를 매우 깊은 수준까지 억제해야 유효성을 확인할 수 있는 질환일 가능성을 시사. 이는 J&J의 니포칼리맙이 류마티스관절염에서는 실패했으며 ACPA 항체 감소율이 낮았던 것과 일관된 방향
Discussion
Related claims
IMVT-1402 in refractory rheumatoid arthritis achieved statistical significance in the Period 2 ACR20 response rate, with the 600mg group meeting key endpoints at week 28 on both ACR20 and ACR50 versus placebo.현대차증권 제약/바이오/의료기기 김현석 · statementImmunovant's Phase 2b trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) demonstrated excellent efficacy and safety, securing the validity of the development strategy.report author · statementThe company's assertion that depth of IgG suppression matters in FcRn indications was clinically demonstrated.하나증권 제약/바이오 김선아 · statementThe 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent efficacy in absolute terms.report author · statementRoivant CEO Matt Gline said on the conference call that they learned exciting, highly competitively valuable things and will say almost nothing about antibody reduction, but have a good amount of confidence going into phase 3.Matt Gline · statementSIM0725 is intended for the treatment of autoimmune diseases.先聲藥業集團 · statement